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ABSTRACT  1 
 2 
Background: Risk scales are used widely for assessing individuals presenting to Emergency 3 
Departments (EDs) following self-harm. There is growing evidence that risk scales have limited clinical 4 
utility in identifying episodes at highest risk of repeat self-harm. However, their cost-effectiveness in 5 
terms of treatment allocation and subsequent repeat self-harm is unknown. We aimed to examine 6 
the cost-effectiveness of five risk scales (SAD PERSONS Scale, Modified SAD PERSONS Scale, ReACT 7 
Self-Harm Rule, Manchester Self-Harm Rule, Barratt Impulsivity Scale) and single item clinician and 8 
patient ratings of risk. 9 
Method: Quality-Adjusted Life Years were estimated for each episode. The five risk scales and the 10 
patient rating were compared to the clinician rating. Incremental cost-effectiveness ratios (ICERs) 11 
were estimated for each scale, using a range of ICER thresholds. Sensitivity analysis explored different 12 
model assumptions. 13 
Results: The formal scales were less cost-effective than the clinician and patient ratings across a range 14 
of ICER thresholds (£0-£30,000). The five scales were also less cost-effective than the clinician rating 15 
in most alternative scenario analyses. However, the clinician rating would be likely to result in 16 
unnecessary treatment costs for over half of patients identified as high risk.  17 
Limitations: Our primary model depended on the assumption that high-intensity care reduced 18 
patients’ risk of further self-harm.  19 
Conclusion: The use of formal assessment tools for managing self-harm presentations to EDs did not 20 
appear to be cost-effective. While the judgement of a mental health clinician was found to be slightly 21 
more cost-effective, it still resulted in incorrect allocation of costs and missed treatment 22 
opportunities. 23 
 24 
  25 
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INTRODUCTION  1 
 2 
Self-harm (intentional self-poisoning or self-injury) is an important public health issue (World Health 3 
Organization, 2014). Over 200,000 people present to emergency departments (EDs) with self-harm 4 
each year in England (Hawton et al., 2007). One in twenty five of these people will die by suicide within 5 
ten years and around 16% will present to hospital with a repeat episode within a year (Carroll et al., 6 
2014). The average cost per attendance to an ED following self-harm was recently estimated to be 7 
£809 (Tsiachristas et al., 2017). However, there is evidence that healthcare costs associated with self-8 
harm are a small fraction of the wider economic costs, notwithstanding the personal costs to 9 
individuals involved (McDaid et al., 2017). 10 
Multiple economic, social and psychological difficulties are associated with self-harm (Barnes et al., 11 
2016; Haw and Hawton, 2008; Hawton et al., 2016a; Hume and Platt, 2007), including complications 12 
due to psychiatric diagnoses (Haw et al., 2001; Haw et al., 2005; Mars et al., 2014), alcohol (Ness et 13 
al., 2015), and stressful life events (Townsend et al., 2016). The medical care of people who self-harm 14 
is often challenging for health services (Sinclair et al., 2011). Potential care strategies vary in intensity 15 
and cost e.g., resource intensive inpatient care versus less costly, less intensive outpatient, community 16 
or primary care (Sinclair et al., 2011).  17 
In England, there are at least 20 risk scales commonly used as part of the assessments to determine 18 
patient management and risk of future self-harm (Quinlivan et al., 2014a). Evidence of their 19 
effectiveness is limited and recommendations about their use vary across clinical guidelines (NICE, 20 
2011; Royal College of Psychiatrists, 2010). The predictive utility of risk scales for repeat self-harm and 21 
suicide is poor (Bolton et al., 2015; Carter et al., 2017; Quinlivan et al., 2016; Quinlivan et al., 2017). 22 
Clinician and patient estimations of risk have been found to outperform existing risk scales in 23 
predicting repeat self-harm, including one of the most widely used scales (the SAD PERSONS scale) 24 
(Quinlivan et al., 2017).  25 
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However, the evidence on the use of risk assessments as interventions is more mixed. Two randomised 1 
controlled trials have been carried out in forensic settings. One found that the use of a structured risk 2 
assessment in the first few days of inpatient admission was associated with reductions in the incidence 3 
of violent episodes (Abderhalden et al., 2008). Another trial including risk assessment as part of an 4 
intervention in outpatient settings found that the assessment was not associated with reductions in 5 
criminal or violent incidents (Troquete et al., 2013). There is limited experimental evidence about risk 6 
assessment as an intervention for people who present to hospital with self-harm. A recent study from 7 
the United States found that combining screening with a brief intervention following an ED 8 
presentation was associated with reductions in repeat suicide attempts and overall number of repeat 9 
attempts (Miller et al., 2017). 10 
While studies to date have examined predictive properties of risk scales, there are few studies of their 11 
associated costs. It is not known if there are any conditions under which a particular scale might be 12 
cost-effective in terms of treatment allocation and subsequent reductions in repeat self-harm.  13 
The objectives of this study were to develop an economic model synthesising clinical and cost-related 14 
evidence to explore: 15 
1. The cost-effectiveness of different risk assessment scales from the perspective of the hospital 16 
service; 17 
2. The potential cost-effectiveness of scales under different conditions. 18 
 19 
METHODS 20 
Before constructing the model, a literature search of the UK National Health Service, Economic 21 
Evaluation Database (https://www.evidence.nhs.uk), a robust collection of published economic 22 
evaluations, was conducted in August 2017 to identify existing modelling studies of self-harm risk 23 
assessments or screening. The search, for studies containing “self-harm” or “suicide” in the title, 24 
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abstract or keywords, returned 40 studies. None presented an economic model relevant to the 1 
present decision problem (25 included drug interventions, 8 focused on psychotherapy interventions; 2 
2 were treatments for patients with schizophrenia, one was a bridge barrier, one was a workplace 3 
intervention, one was a helpline, one was not relevant to suicide or self-harm and one was a 4 
duplicate).  5 
This study followed the Consolidated Health Economic Evaluation Reporting Standards guidance 6 
{Husereau, 2013 #984} (see Table S1 for the checklist). 7 
 8 
Participants 9 
The population of interest for this study were individuals aged 18 years and over attending an 10 
emergency department in England following self-harm.  11 
 12 
Model structure  13 
A data-driven economic model was developed through collaboration with an interdisciplinary team of 14 
health economists, psychiatrists, and clinical researchers (Figure 1). A probability tree mapping out 15 
the immediate consequences of using a risk assessment scale was developed. When a patient 16 
presented at the emergency department after an episode of self-harm, they each had a risk of future 17 
self-harm that was unclear at the time of assessment. A risk assessment gave either a positive result, 18 
predicting the patient as at high risk of repetition, or a negative result, suggesting the patient was low 19 
risk. In the model the branches, or events, correspond to initial true-positive (correctly identified as 20 
high risk of repeat self-harm), false-positive (incorrectly identified as high risk of repeat self-harm), 21 
true-negative (correctly identified as low risk of repeat self-harm) or false-negative (incorrectly 22 
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identified as low risk of repeat self-harm) assessments. Misclassification and the effect of subsequent 1 
care on the risk of repeat self-harm are incorporated in to the economic model separately. 2 
 3 
Figure 1 4 
 5 
Cost-effectiveness model structure  6 
In the model, patients classed as high risk of future self-harm by the risk assessment scale would 7 
receive high-intensity care, for example admission to a psychiatric bed or referral to outpatient 8 
psychiatric treatment. In contrast, those patients identified by the risk scale as having low risk of future 9 
self-harm would receive low-intensity care, which was determined to be one general practitioner (GP) 10 
consultation. 11 
 12 
Patients who repeated self-harm (i.e., true-positive or false-negative risk assessments) were assigned 13 
a probability of further self-harm at any given time, based on real-world repetition rates reported in 14 
observational cohort studies (Table S2). While some individuals could have repeated self-harm and 15 
received care without presenting to the ED, we were interested in hospital treated self-harm, 16 
therefore we assumed that no patients without repeat hospital presentations (i.e., true-negative and 17 
false-positive) repeated self-harm. Patients were able to move into different health states in one-week 18 
cycles. For example, patients who repeated self-harm (either true-positive or false-negative 19 
classifications) could self-harm again and move to the repeat episode state. When a patient repeated 20 
self-harm, they returned to the start of the model, receiving another risk assessment to predict the 21 
likelihood of future self-harm. Those who did not repeat self-harm remained in the ‘no repeat’ health 22 
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state, represented by the semi-circular arrows. Patients could die in any health state, at which point 1 
they were removed from the model.  2 
 3 
In our primary analysis the model was run for three years. While model durations should be sufficient 4 
to capture all major differential outcomes, longer time horizons suffer from increased uncertainty 5 
(NICE, 2013). Furthermore, the highest risk of repeat self-harm is within the first six months of the 6 
index episode (Kapur et al., 2006). In order to reflect society’s higher value placed on costs and 7 
benefits today than in the future (NICE, 2013), and in line with national guidance recommendations, 8 
model outcomes (QALYs and costs) were discounted (reduced) by 3.5% per year.  9 
 10 
Clinical inputs 11 
Clinical data used to populate the model were obtained from a prospective cohort study evaluating 12 
risk scales following hospital-treated self-harm in five hospitals in England. Full details of the study are 13 
reported elsewhere (Quinlivan et al., 2017). In short, that study involved 514 patients aged 18 years 14 
and over who were referred to liaison psychiatry service following self-harm and consented to take 15 
part in a multi-site prospective cohort study evaluating the predictive accuracy of risk scales following 16 
self-harm between March 2014 and January 2015. The liaison psychiatry services were provided by 17 
multi-disciplinary teams which included psychiatric nurses, social workers, consultant psychiatrists, 18 
and junior doctors. For detailed description of the services available, see our earlier study {Quinlivan, 19 
2017 #860}. Patients were referred to liaison psychiatry from the ED, with assessments taking place 20 
either in the ED or on a medical ward. 21 
The assessment scales used in the study were selected on the basis of a systematic review of the 22 
diagnostic accuracy of risk scales following self-harm (Quinlivan et al., 2014b) and a cohort study of 23 
their diagnostic accuracy (Quinlivan et al., 2017). Clinician and patient global ratings of risk of repeated 24 
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self-harm within six months (using a 1-10 Likert-type scale) were also included. Our economic model 1 
included: the SAD PERSONS Scale, Modified SAD PERSONS Scale, ReACT Self-Harm Rule, Manchester 2 
Self-Harm Rule, the Barratt Impulsivity Scale, and clinician and patient ratings.  3 
 4 
Scale predictive accuracy 5 
The predictive accuracy of each scale – sensitivity (correctly predicting repeat self-harm) and 6 
specificity (correctly predicting patients who did not repeat self-harm) – was obtained by comparing 7 
positive/negative assessment results with repeat self-harm episodes (Quinlivan et al., 2017).  8 
 9 
Self-harm episodes 10 
Clinical model inputs are provided in Supplementary Material (Table S2). A key model input was the 11 
underlying proportion of true “high-risk” individuals; that is, those who repeated self-harm and were 12 
identified as at high risk of repeating. In the cohort study 145 (30%) of 483 participants had at least 13 
one repeat episode during the six-month follow-up period (Quinlivan et al., 2017). This figure was used 14 
as the background risk of repetition among the model population. Patients who repeated self-harm 15 
were able to experience multiple further episodes, and this risk increased following each episode 16 
(Quinlivan et al., 2017).   17 
 18 
Resource use and costs 19 
We obtained service use data from the prospective cohort study previously described (Quinlivan et 20 
al., 2017) and from Department of Health statistics (Department of Health, 2015a, b, c). The types of 21 
resource use included in the model were grouped into either self-harm episode care or follow-up care 22 
(Table S2). All self-harm episodes were assumed to present to an emergency department, incurring 23 
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the unit cost of this attendance. A proportion of patients would have required an ambulance to reach 1 
hospital, and some would have been admitted to treat their injuries, incurring additional inpatient 2 
stay costs.  3 
 4 
The model assumed follow-up care was determined by the risk assessment result. A classification of 5 
low risk of repetition caused the patient to be referred back to the care of their GP only. High-intensity 6 
care was provided following a high risk classification, resulting in a potential reduction in risk of repeat 7 
self-harm (see below, ‘Risk reduction’). This was included in the model as several possible referrals, 8 
each incurring more health care resources than low-intensity care: inpatient psychiatric care, 9 
outpatient and community care, social worker support, and specialist drug and alcohol services. The 10 
likelihood of receiving each type of referral was informed by the rates of referrals in the previous 11 
cohort study, excluding those who received only a GP referral. All resource use and cost inputs are 12 
provided in Table S2. 13 
 14 
Risk reduction 15 
There are limited data on the impact of risk assessment results on subsequent clinical management. 16 
Therefore, in order to model the risk reduction potential of the scales in the economic model, we 17 
assumed a positive assessment (whether true or false) would lead to high-intensity care, while a 18 
negative assessment would lead to low-intensity care. The model included the following 19 
assumptions: 20 
• Receiving appropriate high-intensity care prevented repetition in some patients who would 21 
otherwise have repeated self-harm; 22 
• Low-intensity care did not prevent repetition in patients who would otherwise have repeated 23 
self-harm. 24 
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While there is RCT evidence examining the effect of specific psychological treatments (Hawton et al., 1 
2016b), there is limited evidence quantifying the effect of different types of routine management on 2 
repeat self-harm in clinical settings. One study found psychosocial assessment could reduce the risk 3 
of repeat self-harm by 13-57% (Bergen et al., 2010) and another study suggested a 40% reduction, but 4 
only in two out of three of the centres studied (Kapur et al., 2013). Another found an odds ratio for 5 
repeat self-harm of 0.84 favouring psychological intervention over no intervention (Erlangsen et al., 6 
2014). Based on that evidence, in our primary analysis we assumed that high-intensity care caused a 7 
20% risk reduction. The importance of this value was explored in sensitivity analysis. 8 
 9 
Time to repeat episode 10 
Data from the prospective cohort study (Quinlivan et al., 2017) was also used to estimate the rate of 11 
repetition for high-risk patients. Exponential curves provided the best statistical fit to the data overall, 12 
compared to other types of parametric curve, based on the Akaike and Bayesian Information Criteria 13 
(Akaike, 1974; Schwarz, 1978). The resulting constant rate of self-harm was 13% per week for the first 14 
repeat episode, which increased with each further self-harm episode to 39% per week for people who 15 
had more than five repeat episodes. 16 
 17 
Mortality 18 
All-cause mortality outcomes were based on mortality rates from national UK mortality data (ONS, 19 
2015). These values were adjusted to reflect higher mortality among self-harming individuals 20 
(standard mortality ratios were 4.1 for males and 3.2 for females) (Bergen et al., 2012). Mortality rates 21 
were also adjusted to reflect higher risk among those who were admitted to a medical bed following 22 
self-harm (hazard ratio 1.3) (Kapur et al., 2015). 23 
11 
 
 1 
Health economic inputs 2 
 3 
Quality of life 4 
Patient quality of life associated with repeated episodes of self-harm was included in the form of utility 5 
weights, reflecting the value of a particular health state relative to full health (equal to 1), death (equal 6 
to 0) and potentially worse than death (less than 0) (Devlin et al., 2017). Utility weights were combined 7 
with the time spent experiencing them to calculate quality-adjusted life years (QALYs). For example, a 8 
person living for two years with a utility value of 0.82 would accrue (2 * 0.82) = 1.64 QALYs.  9 
We assumed that patients’ quality of life at the start of the model, after the index self-harm episode, 10 
was represented by a utility weight of 0.671. There is no specific utility weight for individuals who have 11 
self-harmed so we used the value corresponding to utility weights for “mental/behavioural problems” 12 
and “personal history of mental disorder” (Sullivan et al., 2011).  13 
Limited evidence exists regarding quality of life during a self-harm episode. A study of 16 Dutch 14 
clinicians (van Spijker et al., 2011) reported a utility decrement of 0.46 attributable to the mental 15 
distress of a suicide attempt, similar to an older Australian study (Mathers et al., 2001). This was 16 
converted to an approximate utility weight by subtracting it from ‘perfect health’: (1 – 0.46) = 0.54. 17 
This utility prevailed during the model cycle in which a patient self-harmed and received emergency 18 
care. Utility then recovered to its previous level, minus an assumed decrement of 0.02 per repeat 19 
episode, to reflect the more severe clinical profile of people who continue to self-harm (Haw et al., 20 
2007).  21 
 22 
Synthesis of health and cost outcomes 23 
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A ‘reference’ risk-assessment scale was selected, and its total cost and QALY results were compared 1 
to each other scale. The clinician global rating was used as the reference scale, because it 2 
corresponded best to usual treatment and might be conceptualised as a ‘no risk assessment scale’ or 3 
‘no intervention’ strategy. For each comparison, the incremental cost-effectiveness ratio (ICER) was 4 
calculated as follows: ICER = Difference in total costs / Difference in total QALYs. ICERs lower than a 5 
given threshold value indicate the intervention is considered to be cost-effective. Until recently this 6 
was typically £20-30,000 of extra spending for each additional QALY gained (NICE, 2013). However, 7 
more recent empirical estimates suggest this value should be around £12,000 (Claxton et al., 2015). 8 
Therefore, we used a threshold value of £12,000, while also examining results using the higher ICER 9 
threshold of £20-30,000.  10 
 11 
Uncertainty analysis 12 
To characterise uncertainty in our model inputs, values were sampled from their underlying 13 
distributions, rather than relying on fixed, potentially imprecise mean values (Table S2). We sampled 14 
all input values 5,000 times for all analyses, then took the average result across those 5,000 unique 15 
“model runs”. This allowed us to present a mean result and a measure of variance around that mean.  16 
Additionally, we tested the sensitivity of our results to different model assumptions, exploring a 17 
number of alternative scenarios to account for the uncertainty around some of the conditions. These 18 
included reducing the underlying proportion of patients who repeated self-harm; assuming no 19 
increase in risk over time; changing the risk reduction associated with high-intensity care; altering the 20 
resources required by outpatient and community care referrals; using a higher ICER threshold and 21 
adjusting the analysis duration. This also allowed us to address our second objective: to see if the cost-22 
effectiveness of the scales changed under different circumstances. 23 
 24 
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RESULTS 1 
The Markov diagram shows the number of episodes in each risk category along with subsequent 2 
management based on the model parameters (Figure 2). The clinician rating classed 47% of the 3 
episodes as being at higher risk of repeat self-harm in the prospective cohort study. According to the 4 
model parameters in the present study, based on 100 self-harm episodes, 25 of these episodes would 5 
have received unnecessary high intensity care (Figure 2). Eight episodes that repeated were missed 6 
and would not have received high intensity care. 7 
 8 
Figure 2 9 
 10 
Cost-effectiveness results  11 
The total QALYs per patient were 1.984 for the clinician rating (Table 1). The MSHR and the ReACT 12 
both produced a QALY gain compared to this reference scale (+0.002).  13 
The SPS, the MSPS and the BIS all resulted in an average net loss of QALYs and increase in costs 14 
compared to the clinician rating. They avoided few repeat episodes as they led to only a small 15 
proportion of patients receiving effective high-intensity care, generating the fewest total QALYs. The 16 
clinician rating dominated (had lower costs and was at least as effective) as the SPS, the MSPS and the 17 
BIS, providing health gains for a lower total cost. The clinician rating also dominated the patient rating 18 
on average. The incremental costs of the patient rating were smaller than the other scales, reflected 19 
in its 22% likelihood of being cost-effective.  20 
Figure 3. shows that no risk-assessment scale was likely to be cost-effective over the clinician rating 21 
across all ICER threshold values. At the upper end of the ICER threshold, higher sensitivity scales (the 22 
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Manchester Self-Harm Rule and the ReACT Self-Harm Rule) had a greater chance of being cost-1 
effective (around 40%).  2 
 3 
Figure 3 4 
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Table 1 
Model cost-effectiveness results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: MSHR: Manchester Self-Harm Rule; ReACT: ReACT Self-Harm Rule; SPS: SAD PERSONS Scale; MSPS: Modified SAD PERSONS Scale 
*Clinician rating is the reference scale; **QALYs: Quality-adjusted life years; ***ICER: incremental cost effectiveness ratio;  ****Dominated: intervention is less costly and 
at least as effective as the comparison scale, i.e. the clinician rating scale (NICE guide to the methods of technology appraisal 2013)
Assessment 
scale 
QALYs**: Mean (SD) 
[95% CI] 
QALYs**: ± reference scale Costs: ± £860 
(the reference 
scale) 
ICER vs. reference 
scale*** 
Likelihood more cost-
effective than clinician 
rating (£12,000 per QALY) 
Clinician rating*  1.984 (0.139) [1.722, 
2.273] 
- -   
 Patient rating 1.983 (0.139) [1.721, 
2.273] 
           0.000 [-0.002, 0.001] £13 [£-20, £55] Dominated by the 
clinician rating**** 
22% 
 ReACT 1.986 (0.139) [1.725, 
2.274] 
0.002 [0, 0.004] £77 [£-6, £145] £34,892 12% 
 MSHR 1.986 (0.139) [1.725, 
2.274] 
0.002 [0, 0.004] £87 [£3, £157] £38,083 9% 
 SPS 1.977 (0.140) [1.715, 
2.269] 
-0.007 [-0.012, 0] £133 [£-65, £512] Dominated by the 
clinician rating 
4% 
 BIS 1.975 (0.140) [1.713, 
2.268] 
-0.008 [-0.015, 0] £201 [£-79, £766] Dominated by the 
clinician rating 
4% 
 MSPS 1.979 (0.139) [1.717, 
2.269] 
-0.005 [-0.010, 0] £101 [£-36, £367] Dominated by the 
clinician rating 
3% 
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Sensitivity analysis 1 
When the underlying proportion of patients who repeated self-harm was reduced, or when the effect 2 
of increasing risk due to continued self-harm was removed, the potential benefit of high-intensity care 3 
was smaller and the BIS and the SPS became more cost-effective (Table 2).  4 
If appropriate high-intensity care was presumed to be more effective – such that 50% of repeat 5 
episodes were avoided – then scales with higher sensitivity, such as the Manchester Self-Harm Rule 6 
and the ReACT Rule, became more cost-effective. However, the clinician rating remained the most 7 
cost-effective on average. Alternatively, under the assumption that high-intensity care caused no 8 
reduction in the risk of repeat self-harm, the Barratt Impulsivity Scale dominated all scales.  9 
Assuming no negative quality of life impact associated with each self-harm episode made higher 10 
sensitivity scales less cost-effective, because the benefit of preventing self-harm was smaller.  11 
If referrals to outpatient and community care required more contacts per patient – rising from two in 12 
the primary analysis to seven, which more closely matches clinical guidelines (NICE, 2011), but may be 13 
less reflective of reality – the SAD PERSONS Scale and Barratt Impulsivity Scale, which would have led 14 
to fewer contacts, became more cost-effective relative to the clinician rating (74-76% likely).  15 
 16 
Shortening the model duration to six months, allowing less time for the small QALY benefits to be 17 
realised, caused both the SAD PERSONS scale and Barratt Impulsivity Scale to be 86% likely to be more 18 
cost-effective than the clinician rating. At 12 months and 60 months, the clinician rating became more 19 
likely to be cost-effective than any of the scales.  20 
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Sensitivity analyses  
(the two scales most likely to be cost-
effective vs. clinician rating are shown) 
Assessment 
scale* 
Incremental QALYs**: Mean 
[95 percentile limits] 
Incremental Costs: 
Mean [95 percentile 
limits] 
Mean ICER*** 
Likelihood more cost-
effective than 
clinician rating 
Underlying risk of any repeat self-harm 
reduced to 21% (Cooper et al., 2015) BIS -0.0032 [-0.0049, 0] -£97 [-£166, -£23] £30,580 93% 
 SPS -0.0026 [-0.0041, 0] -£77 [-£133, -£17] £29,857 92% 
Underlying risk of self-harm repetition does 
not change after each self-harm event 
(fixed) 
 
BIS -0.0037 [-0.0009, 0.0004] -£116 [-£191, -£38] £31,668 95% 
 SPS -0.0030 [-0.0048, 0] -£92[-£152, -£29] £30,819 94% 
Increased effectiveness of high-intensity 
care (50% reduction in risk of self-harm) ReACT 0.0034 [0, 0.0062] £46 [-£32, £110] £13,627 43% 
 MSHR 0.0035 [0, 0.0064] £59 [-£25, £118] £15,386 38% 
No reduction in risk due to high-intensity 
care BIS 0 [0, 0] -£362 [-£544, -£240] 
Dominates the clinician 
rating 100% 
 SPS 0 [0, 0] £298 [-£454, -£195] Dominates the clinician rating 100% 
No utility decrement per episode Patient rating 0 [-0.0003, 0.0001] £13 [-£21, £56] 
Dominated by clinician 
rating 23% 
 SPS -0.0009 [-0.0029, 0] £139 [-£69, £535] Dominated by clinician rating 13% 
Outpatient and community referrals lead to 
7 contacts, on average SPS -0.0066 [-0.0123, 0] -£180 [-£457, £226] £27,127 76% 
 BIS -0.0083 [-0.0153, 0] -£217 [-£586, 365] £26,065 74% 
Time horizon (model duration) of 6 months BIS -0.0008 [-0.0018, 0] -£71 [-£173, £53] £84,125 86% 
 SPS -0.0007 [-0.0014, 0] -£57 [-£138, £44] £82,516 86% 
Time horizon (model duration) of 12 
months SPS -0.0019 [-0.0037, 0] £30 [-£98, £229] 
Dominated by clinician 
rating 28% 
 BIS -0.0024 [-0.0046, 0] £41 [-£125, £299] Dominated by clinician rating 27% 
Time horizon (model duration) of 60 
months ReACT 0.0037 [0, 0.0072] £77 [-£5, £144] £20,659 23% 
 Patient rating -0.0007 [-0.0031, 0.0013] £13 [-£21, £56] 
Dominated by clinician 
rating 21% 
18 
 
Table 2 Sensitivity analyses 
 
 
 
 
 
No discounting of costs or benefits Patient rating -0.0004 [-0.0019, 0.0007] £13 [-£21, £56] 
Dominated by clinician 
rating 21% 
 ReACT 0.0022 [0, 0.0042] £76 [-£5, £144] £34,596 11% 
 
*Abbreviations: MSHR: Manchester Self-Harm Rule; ReACT: ReACT Self-Harm Rule; SPS: SAD PERSONS Scale; MSPS: Modified SAD PERSONS Scale; **ICER: incremental cost 
effectiveness; *** QUALYs: Quality-adjusted life years  
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In order for the Manchester Self-Harm Rule to be cost effective at the threshold of £12,000 per 1 
additional QALY gained, at its existing sensitivity of 97%, the estimated specificity would need to 2 
increase from 20% to 36%. At this level, 45 out of 100 patients would receive unnecessary high 3 
intensity treatment. At the £30,000 threshold, the estimated specificity would need to be 23% 4 
resulting in 54 out of 100 patients receiving unnecessary treatment.  5 
 6 
DISCUSSION  7 
Existing studies of risk assessment tools have focussed on their psychometric properties, such as 8 
sensitivity and positive predictive value for predicting repeat self-harm and future suicide. Economic 9 
modelling provides estimates of costs associated with unnecessary treatment for individuals 10 
incorrectly identified as high risk, and savings associated with effective treatment on quality of life. 11 
This helps to place the use of risk tools in the wider context of the provision of treatment, providing 12 
additional evidence about their effectiveness. Our study suggests that the clinician rating is a more 13 
cost-effective use of clinical resources than the five risk assessment scales we tested. The clinician 14 
rating was also among the most cost-effective approaches in the majority of alternative scenario 15 
analyses we explored; it harboured a ‘middle ground’ between the extremes of high sensitivity and 16 
high specificity of the scales. However, the clinician rating would be likely to result in unnecessary 17 
treatment costs for over half of patients identified as high risk.  Sensitivity analysis suggested it was 18 
unlikely to be cost-effective if high-intensity care was ineffective at reducing self-harm, or when the 19 
underlying proportion of people who repeat self-harm was small.  20 
 21 
Limitations 22 
This is the first economic model developed to assess the cost-effectiveness of self-harm risk 23 
assessment scales in the context of wider clinical services. While existing studies have focused on the 24 
20 
 
accuracy of different scales in predicting repeat self-harm, the present study explores consequences 1 
of risk assessment in terms of health and cost outcomes. A number of scenarios were explored, 2 
helping to account for the uncertainty around the extent of follow-up care received by individuals and 3 
the effects on risks of future self-harm. Predictive accuracy inputs, and some of the resource use 4 
inputs, were taken directly from a recent multi-site prospective cohort study (Quinlivan et al., 2017).  5 
 6 
Presenting reasonable simplifications of clinical reality is necessary of all economic models. In this 7 
model, high-risk patients, without appropriate management, were assumed to experience a future 8 
self-harm episode with certainty, whereas low-risk patients were assumed not to repeat self-harm. 9 
This was a necessary, data-driven assumption, since (i) a true-positive result would not have been true 10 
unless the patient had gone on to repeat self-harm, and (ii) it was necessary to link an assessment 11 
result, indirectly, to the subsequent risk of repetition. 12 
 13 
To characterise uncertainty, a number of sensitivity analyses were tested, capturing major clinical, 14 
economic and modelling assumptions. All analyses were conducted probabilistically to reflect our 15 
uncertainty in the accuracy of model input values.   16 
 17 
Our primary results depended on the assumption that high-intensity care would be effective at 18 
reducing a patient’s risk of further self-harm. While this seems intuitively appropriate, the magnitude 19 
of effectiveness is unclear. Furthermore, in the prospective cohort study, clinicians conducted several 20 
assessment scales to each patient, meaning the results of any particular scale could not be linked to 21 
the care subsequently provided (Quinlivan et al., 2017). In addition, clinicians may have adapted 22 
subsequent treatment based on the battery of assessment results, potentially diluting the predictive 23 
accuracy values of the scales. 24 
21 
 
The prevalence of true positive results may influence the applicability of the findings to other 1 
settings. The repetition rate in the Quinlivan et al. (2017) prospective cohort study was 30%, 2 
indicating relatively high levels of underlying morbidity and need. People who present to emergency 3 
departments and do not receive a mental health assessment or who self-harm in the community are 4 
likely to have a lower repetition rate. This would result in lower predictive accuracy of the scales.  5 
 6 
Clinical and research implications 7 
In a previous study, the formal scales included here were found to have limited clinical utility in  8 
predicting future self-harm, performing either no better, or worse, than the clinicians’ ratings 9 
(Quinlivan et al., 2017). The finding in the present study that they are also unlikely to be cost-effective 10 
provides further evidence that they should not be used alone to determine subsequent treatment and 11 
follow-up care. Even the most cost-effective approach reported in this study, the clinician rating, had 12 
sub-optimal performance in terms of the unnecessary costs associated with treatment for those who 13 
were incorrectly identified as high risk. Given the complexity of self-harm and its associations with a 14 
wide range of health and social difficulties, future research could examine the cost-effectiveness of 15 
treatment referrals in greater detail. For example, cost-effectiveness of referrals to drug and alcohol 16 
services for people with substance misuse or alcohol problems presenting with self-harm could be 17 
examined.  18 
 19 
Further research into the effectiveness of different types of management would also be useful. We 20 
considered effectiveness to be equal across all types of high-intensity referral, an umbrella term 21 
capturing various types of referral over and above referral to a GP. However, it may be appropriate to 22 
differentiate between these types of care in terms of effectiveness.  23 
 24 
22 
 
Conclusion 1 
Previous studies have provided evidence of the predictive accuracy and psychometrics associated with 2 
different risk assessment scales to predict future self-harm. We have developed a cost-effectiveness 3 
model to estimate the health economic consequences of using different scales by exploring what 4 
comes next; that is, the types of clinical services used after a risk assessment. Our results suggested 5 
that the five formal risk scales were less cost-effective than the clinical judgement of a mental health 6 
clinician. Our analysis provides no evidence for the effectiveness of the use of any formal scale or 7 
clinician rating of risk.  8 
 9 
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This paper presents independent research funded by the National Institute for Health Research 11 
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PG-0610-10026). The views expressed are those of the authors and not necessarily those of the NHS, 13 
the NIHR or the Department of Health and Social Care.  14 
 15 
Figure 1:  Figure 1: Cost-effectiveness model structure 16 
 17 
Figure 2:  Markov diagram showing the Clinician Global Rating (based on predictive ability 18 
performance in Quinlivan et al., 2017). 19 
 20 
Figure 3: Cost-effectiveness acceptability curves for the risk scales  21 
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Figure 1: Cost-effectiveness model structure 
 
 
  
The decision tree is on the left and occurs at the start of the model (index episode) to distribute patients 
into Markov health states on the right. High-risk patients may repeat self-harm over time, moving to the 
‘Repeat self-harm episode’ state for 1 week. It is assumed that another risk assessment is conducted in the 
ED, which determines the health state into which the patient re-enters the Markov model. Patients can die 
at any point in the model and move to the ‘Death’ state. 
Key: FN, false negative risk assessment (patient who repeats self-harm is incorrectly determined to be low-
risk); FP, false positive risk assessment (patient who does not repeat self-harm is incorrectly determined to 
be high-risk); TN, true negative risk assessment (patient who does not repeat self-harm is correctly 
determined to be low-risk); TP, true positive risk assessment (patient who repeats self-harm is correctly 
determined to be high-risk). 
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Figure 2: Markov diagram showing the Clinician Global Rating (based on predictive ability 
performance in Quinlivan et al., 2017) 
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Figure 3: Cost-effectiveness acceptability curves for the risk scales   
 
 
Abbreviations: MSHR: Manchester Self-Harm Rule; ReACT: ReACT Self-Harm Rule; SPS: SAD PERSONS 
Scale; MSPS: Modified SAD PERSONS SCALE; Patient rating scale; BIS: Barratt Impulsivity Scale 
 
